['type 2 diabetes mellitus', 'chronic kidney disease stage 4']
['placebo', 'sotagliflozin (sar439954)']

        Inclusion criteria :

          -  Patients with Type 2 Diabetes (drug-naïve or on antidiabetic therapy) and documented
             severe renal insufficiency - CKD4 - defined by an estimated glomerular filtration rate
             (eGFR) equation (based on the 4 variable modification of diet in renal disease (MDRD)
             equation) of ≥15 and <30 mL/min/1.73 m2.

          -  Signed written informed consent to participate in the study in accordance with local
             regulations.

        Exclusion criteria:

          -  At the time of screening, age <18 years.

          -  Hemoglobin A1c (HbA1c) <7% or >11%.

          -  Type 1 diabetes.

          -  Women of childbearing potential (WOCBP) not willing to use highly effective method(s)
             of birth control during the study treatment period and the follow-up period, or who
             are unwilling or unable to be tested for pregnancy during the study.

          -  Treatment with an SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) during
             the last 12 months.

          -  Uncontrolled high blood pressure, severe anemia, severe cardiovascular problems, such
             as heart failure, active cancer, or other conditions that the Investigator believes
             with result in a short life expectancy, will preclude their safe participation in this
             study, or will make implementation of the protocol or interpretation of the study
             results difficult.

          -  Lower extremity complications (such as skin ulcers, infection, osteomyelitis and
             gangrene) identified during the Screening period, and still requiring treatment at
             Randomization.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      